Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

STADA

AstraZeneca AZ

AZ looks beyond diabetes with Forxiga trials

Will investigate dapagliflozin in kidney disease and heart failure

- PMLiVE

FDA knocks back Amgen’s chronic kidney disease treatment

Parsabiv was hoped to equal or exceed solid earner Sensipar

- PMLiVE

Stada CEO departs ahead of proxy battle with activist investors

Hartmut Retzlaff cites health reasons amid rumours of a company sale

- PMLiVE

Updated EMPA-REG data show Jardiance also protects kidney

Boehringer Ingelheim and Lilly’s drug is the first to show positive impact on kidney damage

- PMLiVE

AZ and Inserm collaborate on diabetes and kidney disease

Three-year partnership will look at new therapeutic approaches

- PMLiVE

Atlantis Healthcare win grant for patient support programme

Programme will support chronic kidney disease

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

- PMLiVE

FDA panel turns down Otsuka’s drug for rare kidney disease

Unable to recommend expanded use of tolvaptan

- PMLiVE

AstraZeneca hit by US Pulmicort patent ruling

Federal court says patent for inhaled steroid drug is invalid

- PMLiVE

Baxter expands kidney disease business with $4bn Gambro deal

Strengthens haemodialysis portfolio with purchase of Swedish medical tech firm

- PMLiVE

Abbott stops kidney disease drug trial on safety concerns

Concerns about excess serious adverse events and mortality in patients taking bardoxolone methyl

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links